Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients

Cancer Letters

Volumn 305, Issue 2, 2011, Pages 163-174

  Cesarman, Ethel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AIDS; Castleman disease; EBV HHV 4; KSHV HHV 8; Lymphoma; Lymphoproliferative disorder

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLINE; FLICE INHIBITORY PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; MICRORNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER INCIDENCE; EPSTEIN BARR VIRUS; GAMMAHERPESVIRINAE; GRAFT RECIPIENT; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INFECTIOUS MONONUCLEOSIS; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMABLASTIC LYMPHOMA; PLASMACYTIC HYPERPLASIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; SHORT SURVEY; VIRUS CARCINOGENESIS; VIRUS LATENCY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8;

EID: 79955465167     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.003     Document Type: Review

References (150)

1. Ballon G., Cesarman E. Castleman's disease. Viral and Immunological Malignancies 2006, BC Decker Inc., Hamilton, Ontario, Canada. P.A. Volberding, J. Palefsky (Eds.).
2. Waterston A., Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004, 43:698-704.
3. Soulier J., Grollet L., Oksenhendler E., Cacoub P., Cazals-Hatem D., Babinet P., d'Agay M.-F., Clauvel J.-P., Raphael M., Degos L., Sigaux F. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995, 86:1275-1280.
4. Larroche C., Cacoub P., Soulier J., Oksenhendler E., Clauvel J.P., Piette J.C., Raphael M. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am. J. Hematol. 2002, 69:119-126.
5. Suda T., Katano H., Delsol G., Kakiuchi C., Nakamura T., Shiota M., Sata T., Higashihara M., Mori S. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol. Int. 2001, 51:671-679.
6. Dupin N., Diss T.L., Kellam P., Tulliez M., Du M.Q., Sicard D., Weiss R.A., Isaacson P.G., Boshoff C. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000, 95:1406-1412.
7. Dupin N., Fisher C., Kellam P., Ariad S., Tulliez M., Franck N., van Marck E., Salmon D., Gorin I., Escande J.P., Weiss R.A., Alitalo K., Boshoff C. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. USA 1999, 96:4546-4551.
8. Du M.Q., Liu H., Diss T.C., Ye H., Hamoudi R.A., Dupin N., Meignin V., Oksenhendler E., Boshoff C., Isaacson P.G. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001, 97:2130-2136.
9. Brousset P., Cesarman E., Meggetto F., Lamant L., Delsol G. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi's sarcoma and lymphoid cells of multicentric Castleman's disease. Hum. Pathol. 2001, 32:95-100.
10. Parravicini C., Corbellino M., Paulli M., Magrini U., Lazzarino M., Moore P.S., Chang Y. Chang, Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am. J. Pathol. 1997, 151:1517-1522.
11. Cannon J.S., Nicholas J., Orenstein J.M., Mann R.B., Murray P.G., Browning P.J., DiGiuseppe J.A., Cesarman E., Hayward G.S., Ambinder R.F. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J. Infect. Dis. 1999, 180:824-828.
12. Staskus K.A., Sun R., Miller G., Racz P., Jaslowski A., Metroka C., Brett-Smith H., Haase A.T. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J. Virol. 1999, 73:4181-4187.
13. Menke D.M., Chadbum A., Cesarman E., Green E., Berenson J., Said J., Tiemann M., Parwaresch R., Thome S.D. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of Castleman disease at low risk for HIV infection. Am. J. Clin. Pathol. 2002, 117:268-275.
14. Katano H., Sato Y., Kurata T., Mori S., Sata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000, 269:335-344.
15. Uldrick T.S., Wang V., O'Mahony D., Aleman K., Wyvill K.M., Marshall V., Steinberg S.M., Pittaluga S., Maric I., Whitby D., Tosato G., Little R.F., Yarchoan R. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin. Infect. Dis. 2010, 51:350-358.
16. Simard E.P., Pfeiffer R.M., Engels E.A. Spectrum of cancer risk late after AIDS onset in the United States. Arch. Intern. Med. 2010, 170:1337-1345.
17. Simard E.P., Engels E.A. Cancer as a cause of death among people with AIDS in the United States. Clin. Infect. Dis. 2010, 51:957-962.
18. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003, 4:22-29.
19. Gaidano G., Carbone A., Dalla-Favera R. Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J. Natl. Cancer Inst. Monogr. 1998, 95-100.
20. Knowles D.M. Neoplastic Hematopathology 2001, Williams and Wilkins, Baltimore. second ed.
21. Raphaël M., Said J., Borisch B., Cesarman E., Harris N.L. Lymphomas associated with HIV infection. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 340-342. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele (Eds.).
22. Cesarman E., Dalla-Favera R., Bentley D., Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987, 238:1272-1275.
23. Hamilton-Dutoit S.J., Rea D., Raphael M., Sandvej K., Delecluse H.J., Gisselbrecht C., Marelle L., van Krieken H.J., Pallesen G. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am. J. Pathol. 1993, 143:1072-1085.
24. Touitou R., Arbach H., Cochet C., Feuillard J., Martin A., Raphael M., Joab I. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. J. Gen. Virol. 2003, 84:949-957.
25. Chadburn A., Chiu A., Lee J.Y., Chen X., Hyjek E., Banham A.H., Noy A., Kaplan L.D., Sparano J.A., Bhatia K., Cesarman E. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J. Clin. Oncol. 2009, 27:5039-5048.
26. Dunleavy K., Wilson W.H. Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. J. Clin. Oncol. 2010, 28:e260.
27. Chadburn A., Noy A., Lee J.Y., Hyjek E., Banham A.H., Sparano J.A., Bhatia K., Cesarman E. Reply to K. Dunleavy et al. J. Clin. Oncol. 2010, 28:e261-e262.
28. Kluin P.M., Harris N.L., Stein H., Leoncini L., Raphael M., Campo E., Jaffe E.S. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 265-266. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele (Eds.).
29. Dave S.S., Fu K., Wright G.W., Lam L.T., Kluin P., Boerma E.J., Greiner T.C., Weisenburger D.D., Rosenwald A., Ott G., Muller-Hermelink H.K., Gascoyne R.D., Delabie J., Rimsza L.M., Braziel R.M., Grogan T.M., Campo E., Jaffe E.S., Dave B.J., Sanger W., Bast M., Vose J.M., Armitage J.O., Connors J.M., Smeland E.B., Kvaloy S., Holte H., Fisher R.I., Miller T.P., Montserrat E., Wilson W.H., Bahl M., Zhao H., Yang L., Powell J., Simon R., Chan W.C., Staudt L.M. Molecular diagnosis of Burkitt's lymphoma. New Engl. J. Med. 2006, 354:2431-2442.
30. Hummel M., Bentink S., Berger H., Klapper W., Wessendorf S., Barth T.F., Bernd H.W., Cogliatti S.B., Dierlamm J., Feller A.C., Hansmann M.L., Haralambieva E., Harder L., Hasenclever D., Kuhn M., Lenze D., Lichter P., Martin-Subero J.I., Moller P., Muller-Hermelink H.K., Ott G., Parwaresch R.M., Pott C., Rosenwald A., Rosolowski M., Schwaenen C., Sturzenhofecker B., Szczepanowski M., Trautmann H., Wacker H.H., Spang R., Loeffler M., Trumper L., Stein H., Siebert R. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. New Engl. J. Med. 2006, 354:2419-2430.
31. S.L. Glaser, C.A. Clarke, M.L. Gulley, F.E. Craig, J.A. DiGiuseppe, R.F. Dorfman, R.B. Mann, R.F. Ambinder, Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998, Cancer 98 (2003) 300-309.
32. Carbone A., Gloghini A., Serraino D., Spina M. HIV-associated Hodgkin lymphoma. Curr. Opin. HIV AIDS 2009, 4:3-10.
33. Hummel M., Ziemann K., Lammert H., Pileri S., Sabattini E., Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. New Engl. J. Med. 1995, 333:901-906.
34. Cesarman E., Chang Y., Moore P.S., Said J.W., Knowles D.M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. New Engl. J. Med. 1995, 332:1186-1191.
35. Nador R.G., Cesarman E., Chadburn A., Dawson D.B., Ansari M.Q., Said J., Knowles D.M. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpesvirus. Blood 1996, 88:645-656.
36. Chadburn A., Hyjek E., Mathew S., Cesarman E., Said J., Knowles D.M. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am. J. Surg. Pathol. 2004, 28:1401-1416.
37. Delecluse H.J., Anagnostopoulos I., Dallenbach F., Hummel M., Marafioti T., Schneider U., Huhn D., Schmidt-Westhausen A., Reichart P.A., Gross U., Stein H. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997, 89:1413-1420.
38. Stein H., Harris N.L., Campo E. Plasmablastic lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 256-257. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele (Eds.).
39. Du M.Q., Diss T.C., Liu H., Ye H., Hamoudi R.A., Cabecadas J., Dong H.Y., Harris N.L., Chan J.K., Rees J.W., Dogan A., Isaacson P.G. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002, 100:3415-3418.
40. Dharnidharka V.R., Green M., Webber S.A. Post Transplant Lymphoproliferative Disorders 2010, Springer-Verlag, Berlin-Heidelberg. first ed.
41. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Webber S.A., Chadburn A., Ferry J.A. Post-transplant lymphoproliferative disorders. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon, France.
42. Nalesnik M.A., Jaffe R., Starzl T.E., Demetris A.J., Porter K., Burnham J.A., Makowka L., Ho M., Locker J. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol. 1988, 133:173-192.
43. Knowles D.M., Cesarman E., Chadburn A., Frizzera G., Chen J., Rose E.A., Michler R.E. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995, 85:552-565.
44. Chadburn A., Cesarman E., Knowles D.M. Classification of post-transplantation lymphoproliferative disorders (PT-LPDs) based on morphologic and molecular genetic features has clinical relevance. Lab. Invest. 1997, 76:121A.
45. Cesarman E., Chadburn A., Liu Y.F., Migliazza A., Dalla-Favera R., Knowles D.M. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998, 92:2294-2302.
46. Vakiani E., Nandula S.V., Subramaniyam S., Keller C.E., Alobeid B., Murty V.V., Bhagat G. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum. Pathol. 2007, 38:315-325.
47. Rossi D., Gaidano G., Gloghini A., Deambrogi C., Franceschetti S., Berra E., Cerri M., Vendramin C., Conconi A., Viglio A., Muti G., Oreste P., Morra E., Paulli M., Capello D., Carbone A. Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. Br. J. Haematol. 2003, 123:475-478.
48. Leblond V., Davi F., Charlotte F., Dorent R., Bitker M.O., Sutton L., Gandjbakhch I., Binet J.L., Raphael M. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J. Clin. Oncol. 1998, 16:2052-2059.
49. J.H. Van Krieken, M. Onciu, K.S.J. Elenitoba-Johnson, E.S. Jaffe, Lymphoproliferative diseases associete with primary immune disorders, in: S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele (Eds.), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2008, pp. 336-339.
50. Ilowite N.T., Fligner C.L., Ochs H.D., Brichacek B., Harada S., Haas J.E., Purtilo D.T., Wedgwood R.J. Pulmonary angiitis with atypical lymphoreticular infiltrates in Wiskott-Aldrich syndrome: possible relationship of lymphomatoid granulomatosis and EBV infection. Clin. Immunol. Immunopathol. 1986, 41:479-484.
51. Akashi K., Mizuno S. Epstein-Barr virus-infected natural killer cell leukemia. Leuk. Lymphoma 2000, 40:57-66.
52. Aozasa K., Takakuwa T., Hongyo T., Yang W.I. Nasal NK/T-cell lymphoma: epidemiology and pathogenesis. Int. J. Hematol. 2008, 87:110-117.
53. Quintanilla-Martinez L., Kimura H., Jaffe E.S. EBV-positive T-cell lymphoproliferative disorders of childhood. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 278-280. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele (Eds.).
54. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4:757-768.
55. Klein E., Kis L.L., Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 2007, 26:1297-1305.
56. Kelly G., Bell A., Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 2002, 8:1098-1104.
57. Kelly G.L., Long H.M., Stylianou J., Thomas W.A., Leese A., Bell A.I., Bornkamm G.W., Mautner J., Rickinson A.B., Rowe M. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009, 5:e1000341.
58. Komano J., Maruo S., Kurozumi K., Oda T., Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J. Virol. 1999, 73:9827-9831.
59. Ruf I.K., Rhyne P.W., Yang C., Cleveland J.L., Sample J.T. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J. Virol. 2000, 74:10223-10228.
60. Swaminathan S. Noncoding RNAs produced by oncogenic human herpesviruses. J. Cell Physiol. 2008, 216:321-326.
61. Kitagawa N., Goto M., Kurozumi K., Maruo S., Fukayama M., Naoe T., Yasukawa M., Hino K., Suzuki T., Todo S., Takada K. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. Embo J. 2000, 19:6742-6750.
62. Xing L., Kieff E. Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication. J. Virol. 2007, 81:9967-9975.
63. Cai X., Schafer A., Lu S., Bilello J.P., Desrosiers R.C., Edwards R., Raab-Traub N., Cullen B.R. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2006, 2:e23.
64. Seto E., Moosmann A., Gromminger S., Walz N., Grundhoff A., Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 2010, 6.
65. Heller K.N., Upshaw J., Seyoum B., Zebroski H., Munz C. Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 2007, 109:1138-1146.
66. Staege M.S., Lee S.P., Frisan T., Mautner J., Scholz S., Pajic A., Rickinson A.B., Masucci M.G., Polack A., Bornkamm G.W. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc. Natl. Acad. Sci. USA 2002, 99:4550-4555.
67. God J.M., Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J. Oncol. 2010.
68. Patel P., Hanson D.L., Sullivan P.S., Novak R.M., Moorman A.C., Tong T.C., Holmberg S.D., Brooks J.T. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann. Intern. Med. 2008, 148:728-736.
69. Kieff E., Rickinson A. Epstein-Barr Virus and its replication. Fields Virology 2007, 2603-2655. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. B. Fields, D. Knipe, P. Howley (Eds.).
70. Wilson J.B., Bell J.L., Levine A.J. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo J. 1996, 15:3117-3126.
71. Humme S., Reisbach G., Feederle R., Delecluse H.J., Bousset K., Hammerschmidt W., Schepers A. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA 2003, 100:10989-10994.
72. Kennedy G., Komano J., Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc. Natl. Acad. Sci. USA 2003, 100:14269-14274.
73. Yin Q., Flemington E.K. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 2006, 346:385-393.
74. Dalla-Favera R., Bregni M., Erickson M., Patterson D., Gallo R.C., Croce C.M. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 1982, 79:7824-7827.
75. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991, 88:5413-5417.
76. Nakamura H., Said J.W., Miller C.W., Koeffler H.P. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood 1993, 82:920-926.
77. Horenstein M.G., Nador R.G., Chadburn A., Hyjek E.M., Inghirami G., Knowles D.M., Cesarman E. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus human herpesvirus-8. Blood 1997, 90:1186-1191.
78. Szekely L., Chen F., Teramoto N., Ehlin-Henriksson B., Pokrovskaja K., Szeles A., Manneborg-Sandlund A., Lowbeer M., Lennette E.T., Klein G. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line. J. Gen. Virol. 1998, 79:1445-1452.
79. Rea D., Delecluse H.J., Hamilton-Dutoit S.J., Marelle L., Joab I., Edelman L., Finet J.F., Raphael M. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French study group of pathology for HIV-associated tumors. Ann. Oncol. 1994, 5(Suppl. 1):113-116.
80. Grossman S.R., Johannsen E., Tong X., Yalamanchili R., Kieff E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc. Natl. Acad. Sci. USA 1994, 91:7568-7572.
81. Hsieh J.J., Hayward S.D. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science 1995, 268:560-563.
82. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43:831-840.
83. Kulwichit W., Edwards R.H., Davenport E.M., Baskar J.F., Godfrey V., Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA 1998, 95:11963-11968.
84. Kieser A., Kilger E., Gires O., Ueffing M., Kolch W., Hammerschmidt W. Epstein-barr-virus latent membrane protein-1 triggers ap-1 activity via the c-jun n-terminal kinase cascade. Embo J. 1997, 16:6478-6485.
85. Kilger E., Kieser A., Baumann M., Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998, 17:1700-1709.
86. Eliopoulos A.G., Blake S.M., Floettmann J.E., Rowe M., Young L.S. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 1999, 73:1023-1035.
87. Guasparri I., Bubman D., Cesarman E. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood 2008, 111:3813-3820.
88. Carbone A., Gaidano G., Gloghini A., Larocca L.M., Capello D., Canzonieri V., Antinori A., Tirelli U., Falini B., Dalla-Favera R. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998, 91:747-755.
89. Radkov S.A., Kellam P., Boshoff C. The latent nuclear antigen of kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 2000, 6:1121-1127.
90. Friborg J., Kong W., Hottiger M.O., Nabel G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999, 402:889-894.
91. Fujimuro M., Hayward S.D. Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers. J. Mol. Med. 2004.
92. Bubman D., Guasparri I., Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 2007, 26:4979-4986.
93. Renne R., Barry C., Dittmer D., Compitello N., Brown P.O., Ganem D. Modulation of cellular and viral gene expression by the latency- associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J. Virol. 2001, 75:458-468.
94. Bajaj B.G., Verma S.C., Lan K., Cotter M.A., Woodman Z.L., Robertson E.S. KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity. Virology 2006, 351:18-28.
95. Verma S.C., Borah S., Robertson E.S. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 2004, 78:10348-10359.
96. An J., Lichtenstein A.K., Brent G., Rettig M.B. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood 2002, 99:649-654.
97. Di Bartolo D.L., Cannon M., Liu Y.F., Renne R., Chadburn A., Boshoff C., Cesarman E. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 2008, 111:4731-4740.
98. Rainbow L., Platt G.M., Simpson G.R., Sarid R., Gao S.J., Stoiber H., Herrington C.S., Moore P.S., Schulz T.F. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J. Virol. 1997, 71:5915-5921.
99. Godden-Kent D., Talbot S.J., Boshoff C., Chang Y., Moore P., Weiss R.A., Mittnacht S. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J. Virol. 1997, 71:4193-4198.
100. Li M., Lee H., Yoon D.-W., Albrecht J.-C., Fleckenstein B., Jung J. Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J. Virol. 1997, 71:1984-1991.
101. Ellis M., Chew Y.P., Fallis L., Freddersdorf S., Boshoff C., Weiss R.A., Lu X., Mittnacht S. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex [In Process Citation]. Embo J. 1999, 18:644-653.
102. Mann D.J., Child E.S., Swanton C., Laman H., Jones N. Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J. 1999, 18:654-663.
103. Verschuren E.W., Klefstrom J., Evan G.I., Jones N. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2002, 2:229-241.
104. Verschuren E.W., Hodgson J.G., Gray J.W., Kogan S., Jones N., Evan G.I. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 2004, 64:581-589.
105. Cuomo M.E., Knebel A., Morrice N., Paterson H., Cohen P., Mittnacht S. p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nat. Cell Biol. 2008, 10:723-730.
106. Sarek G., Jarviluoma A., Moore H.M., Tojkander S., Vartia S., Biberfeld P., Laiho M., Ojala P.M. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog. 2010, 6:e1000818.
107. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.L., Schroter M., Scaffidi C., Krammer P.H., Peter M.E., Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521.
108. Chaudhary P.M., Jasmin A., Eby M.T., Hood L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 1999, 14:5738-5746.
109. Matta H., Chaudhary P.M. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc. Natl. Acad. Sci. USA 2004, 101:9399-9404.
110. Guasparri I., Wu H., Cesarman E. The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep. 2006, 7:114-119.
111. Field N., Low W., Daniels M., Howell S., Daviet L., Boshoff C., Collins M. KSHV vFLIP binds to IKK-gamma to activate IKK. J. Cell Sci. 2003, 116:3721-3728.
112. Djerbi M., Screpanti V., Catrina A.I., Bogen B., Biberfeld P., Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors [see comments]. J. Exp. Med. 1999, 190:1025-1032.
113. Guasparri I., Keller S.A., Cesarman E. KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells. J. Exp. Med. 2004, 199:993-1003.
114. Godfrey A., Anderson J., Papanastasiou A., Takeuchi Y., Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005, 105:2510-2518.
115. Lee J.S., Li Q., Lee J.Y., Lee S.H., Jeong J.H., Lee H.R., Chang H., Zhou F.C., Gao S.J., Liang C., Jung J.U. FLIP-mediated autophagy regulation in cell death control. Nat. Cell Biol. 2009, 11:1355-1362.
116. Chugh P., Matta H., Schamus S., Zachariah S., Kumar A., Richardson J.A., Smith A.L., Chaudhary P.M. Constitutive NF-{kappa}B activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc. Natl. Acad. Sci. USA 2005.
117. Ballon G., Chen K., Perez R., Tam W., Cesarman E. Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J. Clin. Invest. 2011, 121:1141-1153.
118. Ahmad A., Groshong J.S., Matta H., Schamus S., Punj V., Robinson L.J., Gill P.S., Chaudhary P.M. Kaposi's sarcoma associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol. Ther. 2010, 10.
119. Brown H.J., Song M.J., Deng H., Wu T.T., Cheng G., Sun R. NF-kappaB inhibits gammaherpesvirus lytic replication. J. Virol. 2003, 77:8532-8540.
120. de Oliveira D.E., Ballon G., Cesarman E. NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol. 2010, 18:248-257.
121. Rivas C., Thlick A.E., Parravicini C., Moore P.S., Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 2001, 75:429-438.
122. Lubyova B., Kellum M.J., Frisancho A.J., Pitha P.M. Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. J. Biol. Chem. 2004, 279:7643-7654.
123. Moore P.S., Boschoff C., Weiss R.A., Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996, 274:1739-1744.
124. Molden J., Chang Y., You Y., Moore P.S., Goldsmith M.A. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J. Biol. Chem. 1997, 272:19625-19631.
125. Nicholas J., Ruvolo V.R., Burns W.H., Sandford G., Wan X.Y., Ciufo D., Hendrickson S.B., Guo H.G., Hayward G.S., Reitz M.S. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat. Med. 1997, 3:287-292.
126. Lee H., Guo J., Li M., Choi J.K., DeMaria M., Rosenzweig M., Jung J.U. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol. Cell Biol. 1998, 18:5219-5228.
127. Brinkmann M.M., Glenn M., Rainbow L., Kieser A., Henke-Gendo C., Schulz T.F. Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J. Virol. 2003, 77:9346-9358.
128. Sharp T.V., Wang H.W., Koumi A., Hollyman D., Endo Y., Ye H., Du M.Q., Boshoff C. K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J. Virol. 2002, 76:802-816.
129. Tomlinson C.C., Damania B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J. Virol. 2004, 78:1918-1927.
130. Prakash O., Swamy O.R., Peng X., Tang Z.Y., Li L., Larson J.E., Cohen J.C., Gill J., Farr G., Wang S., Samaniego F. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 2005, 105:3987-3994.
131. Chandriani S., Ganem D. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 2010, 84:5565-5573.
132. Lee H., Veazey R., Williams K., Li M., Guo J., Neipel F., Fleckenstein B., Lackner A., Desrosiers R.C., Jung J.U. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat. Med. 1998, 4:435-440.
133. Prakash O., Tang Z.Y., Peng X., Coleman R., Gill J., Farr G., Samaniego F. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J. Natl. Cancer Inst. 2002, 94:926-935.
134. Sadler R., Wu L., Forghani B., Renne R., Zhong W., Herndier B., Ganem D. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J. Virol. 1999, 73:5722-5730.
135. Li H., Komatsu T., Dezube B.J., Kaye K.M. The Kaposi's sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. J. Virol. 2002, 76:11880-11888.
136. McCormick C., Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 2005, 307:739-741.
137. Muralidhar S., Pumfery A.M., Hassani M., Sadaie M.R., Azumi N., Kishishita M., Brady J.N., Doniger J., Medveczky P., Rosenthal L.J. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J. Virol. 1998, 72:4980-4988.
138. Kliche S., Nagel W., Kremmer E., Atzler C., Ege A., Knorr T., Koszinowski U., Kolanus W., Haas J. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol. Cell 2001, 7:833-843.
139. Gandy S.Z., Linnstaedt S.D., Muralidhar S., Cashman K.A., Rosenthal L.J., Casey J.L. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. J. Virol. 2007, 81:13544-13551.
140. Choi J.K., Lee B.S., Shim S.N., Li M., Jung J.U. Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. J. Virol. 2000, 74:436-446.
141. Cai X., Lu S., Zhang Z., Gonzalez C.M., Damania B., Cullen B.R. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. USA 2005, 102:5570-5575.
142. Samols M.A., Hu J., Skalsky R.L., Renne R. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J. Virol. 2005, 79:9301-9305.
143. Pfeffer S., Sewer A., Lagos-Quintana M., Sheridan R., Sander C., Grasser F.A., Van Dyk L.F., Ho C.K., Shuman S., Chien M., Russo J.J., Ju J., Randall G., Lindenbach B.D., Rice C.M., Simon V., Ho D.D., Zavolan M., Tuschl T. Identification of microRNAs of the herpesvirus family. Nat. Methods 2005, 2:269-276.
144. Grundhoff A., Sullivan C.S., Ganem D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 2006, 12:733-750.
145. Lei X., Bai Z., Ye F., Xie J., Kim C.G., Huang Y., Gao S.J. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat. Cell Biol. 2010, 12:193-199.
146. Gottwein E., Cullen B.R. A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J. Virol. 2010, 84:5229-5237.
147. Skalsky R.L., Samols M.A., Plaisance K.B., Boss I.W., Riva A., Lopez M.C., Baker H.V., Renne R. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J. Virol. 2007, 81:12836-12845.
148. Gottwein E., Mukherjee N., Sachse C., Frenzel C., Majoros W.H., Chi J.T., Braich R., Manoharan M., Soutschek J., Ohler U., Cullen B.R. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007, 450:1096-1099.
149. DiNardo C.D., Tsai D.E. Treatment advances in posttransplant lymphoproliferative disease. Curr. Opin. Hematol. 2010, 17:368-374.
150. Li N., Thompson S., Schultz D.C., Zhu W., Jiang H., Luo C., Lieberman P.M. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One 2010, 5:e10126.